



Prothena Corporation plc

The Ladenburg Thalmann 2016 Healthcare
Conference
September 27, 2016




Forward-Looking Statements

This presentation contains forward-looking statements. These statements relate to, among other things, the design, proposed mechanism of action and possible clinical benefit of NEOD001; the design and powering of our Phase 2b and Phase 3 studies of NEOD001; the design and proposed mechanism of action of PRX003 and its potential to treat Th17 mediated diseases; the potential of our Phase 1b study of PRX003 to provide a rapid path to proof-of-biology; the proposed mechanism of action of PRX004 on ATTR; the expected timing of providing an update on a Phase 2 development strategy for PRX003; the expected timing of beginning clinical development of PRX004; and the expected timing of announcing data from our Phase 2b study of NEOD001, our Phase 1b study of PRX002 and our Phase 1b study of PRX003. These forward-looking statements are based on estimates, projections and assumptions that may prove not to be accurate, and actual results could differ materially from those anticipated due to known and unknown risks, uncertainties and other factors, including but not limited to the risks, uncertainties and other factors described in the “Risk Factors” sections of our Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on February 25, 2016 and our subsequent Quarterly Reports on Form 10-Q filed with the SEC. Prothena undertakes no obligation to update publicly any forward-looking statements contained in this presentation as a result of new information, future events or changes in Prothena's expectations.



Vision: Deliver novel protein immunotherapies to transform patients' lives



Deep scientific expertise in protein misfolding and cell adhesion, applied toward diseases that lack effective therapies



Executive team with a proven track record of R&D and Commercial innovation



Three mAb programs in clinical development, one in preclinical development, and a discovery engine generating new therapeutic candidates



Strong cash position of \$447 million* at end of 2Q16
Establishing a fully-integrated organization

* Includes cash, cash equivalents and restricted cash

R&D Pipeline for Lead Programs

		PROGRAM	Preclinical	Phase 1	Phase 2	Phase 3	COMMERCIALIZATION RIGHTS
Protein Immunotherapy	Protein Misfolding	NEOD001 AL Amyloidosis <i>Fast Track Designation</i>	The VITAL Amyloidosis Study (Phase 3)			prothena	
			PRONTO (Phase 2b)				
	PRX002 Parkinson's Disease	Phase 1b MAD		prothena Roche			
	PRX004 ATTR Amyloidosis	Preclinical		prothena			
	Cell Adhesion	PRX003 Psoriasis	Phase 1b MAD		prothena		